MUC1免疫疗法。
MUC1 immunotherapy.
作者信息
Beatson Richard E, Taylor-Papadimitriou Joyce, Burchell Joy M
机构信息
Breast Cancer Biology Group, King's College London, Guy's Hospital, London SE1 9RT, UK.
出版信息
Immunotherapy. 2010 May;2(3):305-27. doi: 10.2217/imt.10.17.
PMID:20635898
Abstract
The overexpression and aberrant glycosylation of MUC1 is associated with a wide variety of cancers, making it an ideal target for immunotherapeutic strategies. This review highlights the main avenues of research in this field, focusing on adenocarcinomas, from the preclinical to clinical; the problems and possible solutions associated with each approach; and speculates on the direction of MUC1 immunotherapeutic research over the next 5-10 years.
摘要
MUC1的过表达和异常糖基化与多种癌症相关，使其成为免疫治疗策略的理想靶点。本综述重点介绍了该领域的主要研究途径，聚焦于从临床前到临床阶段的腺癌研究；每种方法相关的问题及可能的解决方案；并对未来5至10年MUC1免疫治疗研究的方向进行了推测。
相似文献
1
MUC1 immunotherapy.MUC1免疫疗法。
Immunotherapy. 2010 May;2(3):305-27. doi: 10.2217/imt.10.17.
2
Update on Mucin-1 immunotherapy in cancer: a clinical perspective.黏蛋白-1在癌症免疫治疗中的最新进展：临床视角
Expert Opin Biol Ther. 2015;15(12):1773-87. doi: 10.1517/14712598.2015.1088519. Epub 2015 Oct 9.
3
Advances of MUC1 as a target for breast cancer immunotherapy.MUC1作为乳腺癌免疫治疗靶点的研究进展
Histol Histopathol. 2007 Aug;22(8):905-22. doi: 10.14670/HH-22.905.
4
MUC1 as a target antigen for cancer immunotherapy.MUC1作为癌症免疫治疗的靶抗原。
Expert Rev Vaccines. 2005 Aug;4(4):493-502. doi: 10.1586/14760584.4.4.493.
5
Modulating MUC1 Function on T Cells.调节 T 细胞上的 MUC1 功能。
Trends Immunol. 2019 Nov;40(11):980-983. doi: 10.1016/j.it.2019.09.007. Epub 2019 Oct 22.
6
Strategies used for MUC1 immunotherapy: human clinical studies.用于MUC1免疫治疗的策略：人体临床研究。
Expert Rev Vaccines. 2008 Sep;7(7):963-75. doi: 10.1586/14760584.7.7.963.
7
Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.靶向免疫疗法旨在治疗表达 MUC1 的实体瘤。
Curr Top Microbiol Immunol. 2017;405:79-97. doi: 10.1007/82_2015_429.
8
Strategies used for MUC1 immunotherapy: preclinical studies.用于MUC1免疫治疗的策略：临床前研究。
Expert Rev Vaccines. 2008 Sep;7(7):951-62. doi: 10.1586/14760584.7.7.951.
9
Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).癌症免疫疗法：TG4010（MVA-MUC1-IL2）的II期临床研究。
J BUON. 2007 Sep;12 Suppl 1:S71-5.
10
Making the most of mucin: a novel target for tumor immunotherapy.充分利用粘蛋白：肿瘤免疫治疗的新靶点。
Cancer Immunol Immunother. 1996 Nov;43(3):142-51. doi: 10.1007/s002620050315.
引用本文的文献
1
Epithelial ovarian cancer is infiltrated by activated effector T cells co-expressing CD39, PD-1, TIM-3, CD137 and interacting with cancer cells and myeloid cells.上皮性卵巢癌被表达 CD39、PD-1、TIM-3、CD137 的活化效应 T 细胞浸润，这些 T 细胞与癌细胞和髓样细胞相互作用。
Front Immunol. 2023 Oct 4;14:1212444. doi: 10.3389/fimmu.2023.1212444. eCollection 2023.
2
Mucins and mucinous ovarian carcinoma: Development, differential diagnosis, and treatment.黏蛋白与黏液性卵巢癌：发生、鉴别诊断及治疗
Heliyon. 2023 Aug 17;9(8):e19221. doi: 10.1016/j.heliyon.2023.e19221. eCollection 2023 Aug.
3
Prospects for the Use of Metal-Based Nanoparticles as Adjuvants for Local Cancer Immunotherapy.基于金属的纳米颗粒作为局部癌症免疫疗法佐剂的应用前景。
Pharmaceutics. 2023 Apr 27;15(5):1346. doi: 10.3390/pharmaceutics15051346.
4
Breast Cancer Vaccine Containing a Novel Toll-like Receptor 7 Agonist and an Aluminum Adjuvant Exerts Antitumor Effects.含有新型 Toll 样受体 7 激动剂和铝佐剂的乳腺癌疫苗发挥抗肿瘤作用。
Int J Mol Sci. 2022 Dec 1;23(23):15130. doi: 10.3390/ijms232315130.
5
Single-cell profiling reveals molecular basis of malignant phenotypes and tumor microenvironments in small bowel adenocarcinomas.单细胞分析揭示了小肠腺癌恶性表型和肿瘤微环境的分子基础。
Cell Discov. 2022 Sep 14;8(1):92. doi: 10.1038/s41421-022-00434-x.
6
A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice.一种靶向MUC1并与PD-L1联合使用的新型治疗性肿瘤疫苗在小鼠体内引发特异性抗肿瘤免疫。
Vaccines (Basel). 2022 Jul 8;10(7):1092. doi: 10.3390/vaccines10071092.
7
Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine.明矾佐剂与内置TLR7激动剂协同增强癌症疫苗的抗MUC1免疫反应。
Front Immunol. 2022 Mar 16;13:857779. doi: 10.3389/fimmu.2022.857779. eCollection 2022.
8
Mucins as anti-cancer targets: perspectives of the glycobiologist.黏蛋白作为抗癌靶点：糖生物学家的观点。
Glycoconj J. 2021 Aug;38(4):459-474. doi: 10.1007/s10719-021-09986-8. Epub 2021 Mar 11.
9
Synthetic MUC1 breast cancer vaccine containing a Toll-like receptor 7 agonist exerts antitumor effects.含有Toll样受体7激动剂的合成MUC1乳腺癌疫苗具有抗肿瘤作用。
Oncol Lett. 2020 Sep;20(3):2369-2377. doi: 10.3892/ol.2020.11762. Epub 2020 Jun 19.
10
CAR-T Cell Therapy-An Overview of Targets in Gastric Cancer.嵌合抗原受体T细胞疗法——胃癌靶点概述
J Clin Med. 2020 Jun 17;9(6):1894. doi: 10.3390/jcm9061894.
Zotero 插件